Skip to content
Homepage
Author:
SOTIO Biotech B.V.
Posted Date:
July 21, 2026
European Patent Office Confirms Patent Protection for SOT201, SOTIO’s Clinical-Stage Immunocytokine Showing Promising Anti-Tumor Activity
SOTIO Biotech B.V.
July 21, 2026
FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer
SOTIO Biotech B.V.
July 14, 2026
SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma
SOTIO Biotech B.V.
June 3, 2026
